4 Reporting rules setup
Each report to NMPA has to be routed to the CDE/CDR Receiver Identifier depending on the case data, such as: Report Type, Primary Reporter Country and Observe Study Type.
Note:
Reporting rules should be set up in Argus with advanced conditions.The below table displays some sample reporting rules.
Country | License type | Agency | Rule name | Timeframe calendar days | Advanced condition |
---|---|---|---|---|---|
China | Marketed Drug | CDR | Death/LT ADR Domestic | 7 | Primary Reporter Country = China Report Type = Spontaneous |
China | Marketed Drug | CDR | Serious ADR Domestic | 15 | Primary Reporter Country = China Report Type = Sponsored Trial Observe Study Type = Individual Patient Use or Other Studies |
United States | Marketed Drug | CDR | Death/LT Foreign | 7 | Primary Reporter Country <> China Report Type = Spontaneous |
United States | Marketed Drug | CDR | Serious ADR Foreign | 15 | Primary Reporter Country <> China Report Type = Sponsored Trial Observe Study Type = Individual Patient Use or Other Studies |
China | Investigational Drug | CDE | SUSAR CT Domestic | 30 | Primary Reporter Country = China Report Type = Sponsored Trial Observe Study Type = Clinical Trial |
United States | Investigational Drug | CDE | SUSAR CT Foreign | 30 | Primary Reporter Country <> China Report Type = Sponsored Trial Observe Study Type = Clinical Trial |
The following table describes the set of criteria for the Report Category (C.1.CN.2). All mappings, validations and conformance are formed based on this criteria.
C.1.CN.2 Reporting Category | Criteria |
---|---|
Domestic Study Case (NMPA code = 11) |
|
Domestic Post-Market Case (NMPA code = 12) |
|
Foreign Study Case (NMPA code = 21) |
|
Foreign Post-Market Case (NMPA code = 22) |
|